FDA has approved perioperative pembrolizumab for resectable head and neck squamous cell carcinoma, but do patients need ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors ...

Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in ...

Now, nivolumab -- in combination with chemotherapy -- is indicated for the first-line treatment of adults with unresectable ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously ...

The FDA approved pembrolizumab (Keytruda) for patients with PD-L1-positive resectable locally advanced head and neck squamous ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...